English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/52344
Share/Impact:
Statistics
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar a otros formatos:
DC FieldValueLanguage
dc.contributor.authorYerbes, Rosario-
dc.contributor.authorPalacios, Carmen-
dc.contributor.authorLópez-Rivas, Abelardo-
dc.date.accessioned2012-06-27T11:18:56Z-
dc.date.available2012-06-27T11:18:56Z-
dc.date.issued2011-12-13-
dc.identifierissn: 1699-048X-
dc.identifiere-issn: 1699-3055-
dc.identifier.citationClinical and Translational Oncology 13(12): 839-847 (2011)-
dc.identifier.urihttp://hdl.handle.net/10261/52344-
dc.description.abstractIn tumour cells, activation of the apoptotic machinery by death receptor ligands of the tumour necrosis factor (TNF) receptor superfamily of cytokines represents a novel therapeutic strategy. However, systemic treatment of tumours with TNF-α and CD95 ligand may produce severe toxic effects. The tumour necrosis-related apoptosisinducing ligand (TRAIL) is a member of the TNF family capable of inducing apoptosis in a wide variety of cancer cells upon binding to pro-apoptotic receptors, while having no effect on the majority of normal human cells tested. Interestingly, preclinical studies in mice and nonhuman primates showed no systemic cytotoxicity upon injection of either recombinant TRAIL or agonistic TRAIL-receptor antibodies. Furthermore, these treatments have been shown to effectively suppress the growth of a range of tumour xenografts. Although unwanted effects of some TRAIL preparations have been reported in normal cells, the use of TRAIL receptor agonists could represent a suitable approach in cancer therapy. Here, we shall review our current understanding of apoptotic and non-apoptotic TRAIL signalling, the therapeutic potential of TRAIL-based approaches in cancer treatment, and the results of phase 1 and 2 clinical trials with recombinant TRAIL or agonistic TRAIL receptor antibodies, either as monotherapy or in combination with other chemotherapeutic agents.-
dc.language.isoeng-
dc.publisherSpringer-
dc.rightsclosedAccess-
dc.subjectTRAIL-
dc.subjectApoptosis-
dc.subjectCancer-
dc.subjectTherapy-
dc.subjectClinical trials-
dc.titleThe therapeutic potential of TRAIL receptor signalling in cancer cells-
dc.typeArtículo-
dc.identifier.doi10.1007/s12094-011-0744-4-
dc.date.updated2012-06-27T11:18:56Z-
dc.description.versionPeer Reviewed-
dc.relation.csic-
Appears in Collections:(CABIMER) Artículos
Files in This Item:
File Description SizeFormat 
accesoRestringido.pdf15,38 kBAdobe PDFThumbnail
View/Open
Show simple item record
 

Related articles:


WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.